Cholecystokinin Octapeptide Ammonium: Evidence Map
2026-10-03
Cholecystokinin octapeptide ammonium is examined as a sulfation-dependent, receptor-linked research probe rather than a generic peptide agonist. This evidence map connects the foundational electroacupuncture study with modern questions in neurobiology, immunity, behavior, and cardiac endocrine signaling while defining key interpretation limits.
Intravesical p21 mRNA-LNP Therapy for Bladder Cancer
2026-10-02
The reference study develops a localized tumor-suppressor replacement strategy in which chemically modified p21 mRNA is encapsulated in lipid nanoparticles and delivered intravesically. In cell and orthotopic mouse models, p21-LNP restored nuclear p21, disrupted cell-cycle progression, increased DNA-damage signaling and apoptosis, and suppressed bladder tumor growth with limited systemic distribution.
MitMAB for Organoid Uptake Mechanism Studies
2026-10-01
MitMAB is a dynamin-targeting endocytosis research compound for testing how extracellular vesicles enter polarized intestinal models. This guide translates milk-derived extracellular vesicle findings into an orientation-aware assay strategy that separates uptake, membrane binding, and cellular toxicity.
Trilaurin Workflows for Oral Lipid Delivery
2026-10-01
Trilaurin, also known as Glycerol Tridodecanoate, gives formulation scientists a defined C12 triacylglycerol for studying lipid digestion, peptide protection, and controlled release. The same substrate also supports lipase-based fatty amine synthesis, making it useful across pharmaceutical formulation and biocatalysis workflows.
In Vitro Embryonic Dormancy via mTOR Inhibition
2026-09-30
This Nature Protocols study converts pharmacological mTOR inhibition into a reproducible, reversible method for placing mouse blastocysts, human blastoids, and mouse or human pluripotent stem cells into a diapause-like state. Its practical contribution is a scalable alternative to invasive in vivo procedures, together with experimental controls and readouts for distinguishing genuine dormancy from irreversible developmental damage.
Western Secondary Antibody Dilution Buffer: Mechanism
2026-09-30
Discover how Western Secondary Antibody Dilution Buffer supports analytically rigorous protein detection Western blot workflows. This article connects K4115 formulation logic with causal evidence from NHE1, Olfr2, calcium-dependent ROS, and macrophage inflammation research.
PD 0332991: CDK4/6 Workflow & Troubleshooting
2026-09-29
Build reproducible cell-cycle, viability, and Rb-pathway assays with PD 0332991 (Palbociclib) HCl. This guide emphasizes mechanism-matched model selection, practical dosing workflows, orthogonal readouts, and troubleshooting strategies that distinguish true G1 arrest from nonspecific assay effects.
Nav1.5 Ser571, Late INa, and Cardiac Aging
2026-09-29
The 2024 reference study identifies Nav1.5 phosphorylation at Ser571 as a mechanistic link between increased late sodium current, delayed ventricular repolarization, and impaired diastolic relaxation during cardiac aging. Its combination of age-stratified mice, phosphomimetic and phosphoablated channel models, electrophysiology, calcium imaging, and myocyte mechanics provides a useful framework for studying late-current-dependent cardiac dysfunction.
A Cardiac MPS Predicts LNP–mRNA Heart Delivery
2026-09-28
This study uses a three-dimensional human cardiac microphysiological system (MPS) to screen lipid nanoparticle–mRNA formulations and identify candidates with improved heart transfection in vivo. Acid-degradable PEG–lipid formulations performed well in the cardiac model and showed stronger heart delivery with lower liver uptake than standard formulations in mice, highlighting the value—and current limits—of tissue-level screening.
Belinostat (PXD101): Reading Drug Response Correctly
2026-09-27
Belinostat (PXD101) can inhibit tumor-cell growth, but a viability result alone cannot show whether cells stopped proliferating or died. This article applies a measurement-focused framework to interpreting its effects in bladder and prostate cancer models and choosing complementary readouts.
BMS-345541 for NF-κB Pathway Research
2026-09-26
Use BMS-345541 to test whether IKK-dependent NF-κB signaling contributes to cytokine responses, endothelial angiogenesis, or cancer-cell phenotypes. This workflow connects pathway inhibition to practical controls and readouts while distinguishing the limb-ischemia study’s findings from broader applications.
MK-8745: Aurora A Inhibitor Workflows
2026-09-26
Use MK-8745 to connect Aurora A inhibition with mitotic arrest, tetraploidy, and apoptosis in genotype-aware cancer assays. A practical workflow pairs its cell-based effects with the retinoblastoma study’s AURKA findings—while keeping clear that MK-8745 itself has not been established as a retinoblastoma treatment.
Reactive Oxygen Species Assay Kit in Myogenesis
2026-09-25
The Reactive Oxygen Species Assay Kit can help quantify intracellular oxidation in live-cell studies, but interpreting fluorescence requires more than reading a signal. Using research on tetrandrine-treated black sea bream myogenic cells, this article explains how to distinguish ROS association from causation and design more informative experiments.
Novobiocin Sodium in DNA Replication Assays
2026-09-25
Use Novobiocin Sodium to test how bacterial DNA replication relates to protoplast enlargement, membrane synthesis, and vacuole formation—not simply to score growth inhibition. A staged, time-of-addition workflow helps distinguish early from late effects and pairs microscopy with DNA quantification for stronger interpretation.
SB-3CT Workflows for MMP9 and PNN Research
2026-09-24
Connect the Adamtsl3–MMP9 perineuronal-net findings to practical SB-3CT assay design, from target engagement to tissue readouts. The workflow highlights a critical selectivity caveat: SB-3CT is substantially more potent against MMP-2 than MMP-9, so MMP9-specific conclusions need orthogonal controls.